Therefore, the development of point-of-care testing (also known as a rapid bedside test) for these proteins, especially S100A8/A9, in AF is required to improve the clinical application of the biomarkers for assessing pregnancy outcome after placement of the rescue cerclage. The gene discussed is IGKV1D-22; the disease is atrial fibrillation.